ArticleScientific reports2025
Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma.
Takafumi Fukushima et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it